| Previous Close | 34.06 |
| Open | 34.08 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 33.97 - 34.22 |
| 52 Week Range | 29.83 - 37.39 |
| Volume | 30,046,310 |
| Avg. Volume | 21,623,077 |
| Market Cap | 203.92B |
| Beta | 1.06 |
| PE Ratio (TTM) | 28.76 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.76%) |
| Ex-Dividend Date | 2017-05-10 |
| 1y Target Est | N/A |
- Motley Fool•20 hours ago
Portola Pharmaceuticals' FDA Nod Could Spark M&A Interest
The FDA has approved its first commercial medicine, and because it could reshape a big indication, the company may have just gotten a lot more interesting to suitors.
- TheStreet.com•yesterday
15 Great Dividend Stocks to Own Should the Surging Stock Market Plunge This Summer
Here are the names.
- Moody's•2 days ago
Greenwich Capital Commercial Funding Corp., 2005-GG3 -- Moody's Affirms Four Classes of GCCFC 2005-GG3
Rating Action: Moody's Affirms Four Classes of GCCFC 2005- GG3. Global Credit Research- 23 Jun 2017. Approximately $86.3 Million of Structured Securities Affected.
